Treatment of metastatic renal cell cancer (RCC) with antiangiogenic agents that block vascular endothelial growth factor (VEGF) receptor 2 signaling produces tumor regression in a substantial fraction of patients; however resistance typically develops within 6-12 months. The purpose of this study was to identify molecular pathways involved in resistance.
Introduction
The pathogenesis of renal cell carcinoma (RCC) frequently involves the inactivation of the von Hippel Lindau (VHL) tumor suppressor gene which encodes an E3 ubiquitin ligase complex that targets hypoxia-inducible factor (HIF) for proteasome-mediated degradation. In the setting of VHL inactivation, a large repertoire of hypoxia inducible genes including VEGF and platelet derived growth factor (PDGF) is overexpressed (1) . This increase in proangiogenic factors, even in the absence of hypoxia, likely accounts for the nearly unique sensitivity of RCC to treatment with small molecule tyrosine kinase inhibitors (TKIs) of the VEGF receptor (VEGFR) such as sunitinib and sorafenib. Treatment of patients with RCC with these agents frequently leads to tumor regression, but resistance to treatment typically develops within 1 year, substantially limiting their benefit (2-6).
This acquired "evasive" resistance to VEGF pathway inhibition has been observed in multiple preclinical models and tumor types (7) . In these settings proposed resistance mechanisms include an increase in alternative proangiogenic factors such as IL-8 and bFGF as seen in the setting of anti-VEGFR2 antibody therapy (8, 9) . The empty basement membrane sheaths and pericyte changes seen by Mancuso et al could also provide the scaffold for tumor angiogenesis in the resistant setting (10) . Other suggested mechanisms include selection of cells that can better tolerate hypoxia (11) and, in the setting of intrinsic resistance to VEGF inhibition, the recruitment of CD11b and Gr1+ bone marrow derived proangiogenic cells (12) . Elucidation of the mechanisms underlying the acquired resistance to VEGFR blockade in RCC may contribute to the development of novel therapeutic approaches that could enhance the efficacy of VEGFR inhibitors in this patient population.
Interferon gamma (IFNγ) signaling leads to the production of three angiostatic chemokines, CXCL9-11 (mig, IP-10 and ITAC) (13) . These chemokines are highly expressed in RCC relative to normal kidney and have been associated with favorable prognosis in patients with RCC (14, 15) . Moreover, CXCR3, the receptor for RCC cell lines were harvested from subconfluent cultures by a brief exposure to 0.25% trypsin and 0.02%
EDTA. Trypsinization was stopped with medium containing 10% FBS, and the cells were washed once in serum-free medium and resuspended in phosphate buffered saline (PBS). Only suspensions consisting of single cells with greater than 90% viability were used for the injections.
To establish RCC tumor xenografts, 786-O or A498 tumor cells were injected subcutaneously (1 x 10 7 cells)
into the flanks of 6-8 week old mice that were of 20 gm average body weight. Tumors developed in > 80% of the mice and were usually visible within a few days of implantation. Sorafenib (80 mg/kg, Bayer) or sunitinib (additive-free, 53.6 mg/kg, Pfizer) was administered 6 out of 7 days per week by gavage beginning when the tumors had grown to a diameter of 12 mm as per (21, 22) . Tumors were measured daily while on treatment and the day of resistance recorded. Resistance was defined as an increase tumor diameter by 2mm from its pretreatment size of 12mm. This difference represents the smallest increase in size that could be reproducibly measured by calipers and is roughly analogous to the clinical criteria for resistance (20% growth by RECIST) used in patients. Furthermore, this difference was previously shown to be associated with restored angiogenesis in this model (22) . Tumor long and short axes were measured and long axis and tumor volume were followed to determine growth curves. Treatment was continued until tumors grew to 20 mm at which point the mice were sacrificed. Tumor tissue was obtained pre-treatment, during response and at time of resistance for various analyses described below.
CXCL9 administration
CXCL9 (1 ug in 200ul: R&D systems) was injected into the central portion of tumor xenografts thrice weekly as described previously (18) . Control mice received injections of PBS, the vehicle in which the CXCL9 was dissolved. Injections began when tumors reached 12 mm and were given either alone or concomitant with 7
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Immunohistochemistry
For CD34 analysis, 4um thick sections were prepared from formalin-fixed, paraffin-embedded tumor specimens. Sections were deparaffinized, rehydrated and heated with a pressure cooker to 125°C for 30 seconds in citrate buffer for antigen retrieval. After cooling to room temperature, sections were incubated in 3%
hydrogen peroxide for 5 minutes to quench endogenous peroxidase, and then for 20 minutes in Dako serumfree protein block (Dako, Carpinteria, CA). The anti-CD34 antibody (Abcam, Cambridge, MA) was applied at a 1:100 dilution to sections for 1 hour, followed by rabbit anti-goat secondary antibody for 30 minutes. Detection was performed by incubating with Dako EnVision+ System HRP labeled polymer anti-rabbit for 30 minutes, followed by DAB chromogen. Slides were scanned using the Scanscope XT (Aperio Technologies Inc., Visa, CA.) and analyzed using a modified Microvessel analysis algorithm (Aperio Technologies Inc).
For IFNγR staining, frozen OCT sections were used. Sections were fixed in -20C acetone for 5 minutes and then air-dried. Sections were incubated in 3% hydrogen peroxide for 5 minutes to quench endogenous peroxidase. The anti-IFNγR antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was applied at a 1:50 dilution to sections for 1 hour. Detection was performed by incubating with Dako EnVision + System HRP labeled polymer anti-mouse for 30 minutes, followed by DAB chromogen.
Tumor perfusion imaging
Tumor perfusion imaging (Arterial Spin Labeled (ASL) MRI) was performed as previously described (22) . ASL sequence raw data were saved and transferred to the analysis workstation for image reconstruction by using custom software written within the Interactive Data Language (IDL; research Systems, Boulder, Co). The ASL To determine tumor perfusion, a region of interest was drawn freehand around the peripheral margin of the tumor by using an electronic cursor on the reference image that was then copied to the perfusion image. The mean blood flow for the tumor tissue within the region of interest was derived, and image window and level were fixed. A 16-color table was applied in 10 mL/100 g/min increments ranging from 0 to 160 mL/100 g/min,
with flow values represented as varying shades of black, blue, green, yellow, red, and purple, in order of increasing perfusion.
Results

Modulation of IFNγ signaling with VEGFR inhibitor therapy
786-O derived tumors were implanted into mice as described in the Methods section. Treatment with sunitinib or sorafenib was initiated at a tumor size of 12mm in long axis. Tumors exhibited a period of growth stabilization followed by growth resumption despite continued therapy as previously described (22) . Plasma was collected from untreated mice (n=12), day 3 (n=16) and at resistance (n=13). Twenty-seven cytokines were screened using human specific panels and 23 cytokines were screened using murine specific panels.
Changes in several cytokines were noted in both the tumor and the stroma at the time of resistance (Supplemental table 1) including a significant decrease in the production of IFNγ (P=0.018 for day 3 vs resistant and 0.0120 for untreated vs. resistant) ( Figure 1A ). Human cytokines are tumor derived in this system; these findings suggest that tumor-derived IFNγ may be down-modulated with resistance. Other significant changes were observed in several immune cytokines including decreased human GM-CSF and G-CSF and, as previously reported, increased human IL-8 at resistance (24) . Significant changes in murine IL-3, IL-4, IL-13, TNFα and GM-CSF were also noted ( Figure S1 ). To further define the changes in the IFNγ pathway that accompany resistance to sorafenib and sunitinib, the expression of the angiostatic chemokines regulated by IFNγ was analyzed. Western analysis of the tumors at day 3 of therapy and at the time of resistance shows a loss of all three chemokines (CXCL9-11) relative to untreated tumors ( Figure 2 ). This is consistent with the hypothesis that VEGFR TKI treatment leads to decrease in IFNγ signaling.
Chemokine administration delays the development of resistance to sunitinib
The treatment induced loss of angiostatic chemokines led to the hypothesis that resistance could be delayed with chemokine replacement. To study this, CXCL9 was injected into the 786-O tumors either alone or concomitant with sunitinib gavage. CXCL9 was selected because of the prior data that this chemokine exhibits activity in murine RCC models (18) . 
Discussion
Treatment of patients with the VEGFR TKIs sorafenib and sunitinib can lead to periods of tumor stability but resistance to therapy is inevitable. We have used a mouse model to define mechanisms by which resistance develops and have found that components of the IFNγ signaling pathway are lost with sunitinib or sorafenib therapy. Our data also show that CXCL9 treatment delays resistance to sunitinib in 786-O and A498 derived tumors and that one mechanism by which this occurs is by prolongation of antiangiogenic effects of sunitinib.
These data suggest that angiostatic pathways are suppressed as a result of VEGFR TKI therapy and set the stage for the subsequent development of resistance to therapy. 
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In the setting of VEGFR inhibition, RCC tumors undergo extensive necrosis (22) . In the setting of this necrosis and accompanying hypoxia/nutrient deprivation, tumors may undergo compensatory changes including the induction of salvage angiogenesis pathways. We propose that the environmental stress resultant from a rapid and dramatic reduction in tumor vasculature and VEGFR signaling is particularly conducive to the development of such molecular changes. We hypothesize that one of these molecular changes is the loss of IFNγR and that this loss is linked to the downmodulation of angiostatic chemokines. Thus, this revascularization of VEGFdeprived tumors is likely physiologically distinct from de novo angiogenesis.
Within just a few days of therapy, RCC xenografts appear particularly vulnerable to agents that could prevent salvage angiogenesis. In fact, we show an early loss (by day 3 of treatment) of IFNγR and CXCL9, which led to our hypothesis that treatment with CXCL9, must be administered early. Thus we administered sunitinib and CXCL9 concurrently in an effort to overcome possible changes resulting from this early loss of angiostasis.
While other recently published studies have shown that antiangiogenic therapy can lead to increased production of angiogenic molecules and increased invasiveness and metastatic potential (25, 26) , we show that antiangiogenic therapy also leads to down modulation of angiostatic signaling.
CXCR3, the receptor for CXCL9, is expressed on both tumor cells and endothelium. CXCR3 signaling in other tumor types has pro-invasive properties (27) . By contrast, RCC xenografts in our models did not show accelerated growth compared to untreated tumors when injected with single agent CXCL9. This is consistent with the finding that CXCR3 expression confers a favorable prognosis in patients with localized RCC (28) . shown similar findings with sorafenib treatment (22) . We did note, however, that the restored tumor perfusion at the time a resistance never reaches the pretreatment levels. This finding suggests that angiogenesisindependent factors may also contribute to resistance to VEGFR blockade. For example, metabolic changes in a tumor may occur that limit its oxygen requirements relative to the treatment naïve setting (31) . Figure 6C shows the Western analysis for IFNγR and CXCL9 in A498 tumors in representative untreated tumors (un), day 
